O	0	8	Clinical
O	9	17	outcomes
O	18	20	of
O	21	27	ethnic
O	28	36	minority
O	37	42	women
O	43	45	in
O	46	48	MA
O	48	49	.
O	49	51	17
O	51	52	:
O	53	54	a
O	55	60	trial
O	61	63	of
B-intervention	64	73	letrozole
O	74	79	after
O	80	81	5
O	82	87	years
O	88	90	of
O	91	100	tamoxifen
O	101	103	in
O	104	118	postmenopausal
O	119	124	women
O	125	129	with
O	130	135	early
O	136	141	stage
O	142	148	breast
O	149	155	cancer
O	155	156	.

O	157	166	Aromatase
O	167	177	inhibitors
O	178	181	are
O	182	188	widely
O	189	197	employed
O	198	200	in
O	201	204	the
O	205	213	adjuvant
O	214	223	treatment
O	224	226	of
O	227	232	early
O	233	238	stage
O	239	245	breast
O	246	252	cancer
O	252	253	.

O	254	257	The
O	258	264	impact
O	265	267	of
O	268	277	aromatase
O	278	288	inhibitors
O	289	292	has
O	293	296	not
O	297	301	been
O	302	313	established
O	314	316	in
O	317	323	ethnic
O	324	332	minority
O	333	338	women
O	338	339	.

O	340	343	The
O	344	351	purpose
O	352	354	of
O	355	359	this
O	360	365	study
O	366	369	was
O	370	372	to
O	373	381	evaluate
O	382	385	the
O	386	392	impact
O	393	395	of
O	396	405	letrozole
O	406	408	on
O	409	417	minority
O	418	423	women
O	424	426	in
O	427	429	MA
O	429	430	.
O	430	432	17
O	432	433	,
O	434	435	a
O	436	443	placebo
O	443	444	-
O	444	454	controlled
O	455	460	trial
O	461	463	of
O	464	473	letrozole
O	474	483	following
O	484	485	5
O	486	491	years
O	492	494	of
O	495	504	tamoxifen
O	505	507	in
B-eligibility	508	522	postmenopausal
I-eligibility	523	528	women
I-eligibility	529	533	with
I-eligibility	534	539	early
I-eligibility	540	545	stage
I-eligibility	546	552	breast
I-eligibility	553	559	cancer
O	559	560	.

O	561	574	Retrospective
O	575	585	comparison
O	586	588	of
O	589	596	disease
O	596	597	-
O	597	601	free
O	602	610	survival
O	611	612	(
O	612	615	DFS
O	615	616	)
O	616	617	,
O	618	622	side
O	623	630	effects
O	630	631	,
O	632	635	and
O	636	640	mean
O	641	648	changes
O	649	651	in
O	652	659	quality
O	660	662	of
O	663	667	life
O	668	669	(
O	669	672	QOL
O	672	673	)
O	674	680	scores
O	681	685	from
O	686	694	baseline
O	695	702	between
B-ethinicity	703	712	Caucasian
O	713	716	and
O	717	725	minority
O	726	731	women
O	732	735	was
O	736	745	performed
O	745	746	.

B-intervention	747	755	Minority
O	756	757	(
O	757	758	n
O	759	760	=
B-intervention-participants	761	764	352
O	764	765	)
O	766	769	and
B-control	770	779	Caucasian
O	780	781	(
O	781	782	n
O	783	784	=
B-control-participants	785	789	4708
O	789	790	)
O	791	796	women
O	797	801	were
O	802	810	analyzed
O	810	811	.

O	812	817	There
O	818	821	was
O	822	824	no
O	825	835	difference
O	836	843	between
O	844	849	these
O	850	856	groups
O	857	859	in
B-outcome	860	863	DFS
O	864	865	(
B-iv-bin-percent	865	867	91
I-iv-bin-percent	867	868	.
I-iv-bin-percent	868	869	6
I-iv-bin-percent	869	870	%
O	871	877	versus
B-cv-bin-percent	878	880	92
I-cv-bin-percent	880	881	.
I-cv-bin-percent	881	882	4
I-cv-bin-percent	882	883	%
O	884	896	respectively
O	897	900	for
O	901	902	4
O	903	907	year
O	908	911	DFS
O	911	912	)
O	912	913	.

O	914	923	Letrozole
O	923	924	,
O	925	933	compared
O	934	938	with
O	939	946	placebo
O	946	947	,
O	948	961	significantly
O	962	970	improved
B-outcome	971	974	DFS
O	975	978	for
O	979	989	Caucasians
O	990	991	(
O	991	993	HR
O	994	995	=
O	996	997	0
O	997	998	.
O	998	1000	55
O	1000	1001	;
O	1002	1003	P
O	1004	1005	<
O	1006	1007	0
O	1007	1008	.
O	1008	1012	0001
O	1012	1013	)
O	1014	1017	but
O	1018	1021	not
O	1022	1025	for
O	1026	1036	minorities
O	1037	1038	(
O	1038	1040	HR
O	1041	1042	=
O	1043	1044	1
O	1044	1045	.
O	1045	1047	39
O	1047	1048	;
O	1049	1050	P
O	1051	1052	=
O	1053	1054	0
O	1054	1055	.
O	1055	1057	53
O	1057	1058	)
O	1058	1059	.

O	1060	1065	Among
O	1066	1071	women
O	1072	1075	who
O	1076	1084	received
O	1085	1094	letrozole
O	1094	1095	,
O	1096	1106	minorities
O	1107	1110	had
O	1111	1112	a
O	1113	1126	significantly
O	1127	1132	lower
B-outcome	1133	1142	incidence
I-outcome	1143	1145	of
I-outcome	1146	1149	hot
I-outcome	1150	1157	flashes
O	1158	1159	(
B-iv-bin-percent	1159	1161	49
I-iv-bin-percent	1161	1162	%
O	1163	1169	versus
B-cv-bin-percent	1170	1172	58
I-cv-bin-percent	1172	1173	%
O	1173	1174	;
O	1175	1176	P
O	1177	1178	=
O	1179	1180	0
O	1180	1181	.
O	1181	1183	02
O	1183	1184	)
O	1184	1185	,
B-outcome	1186	1193	fatigue
O	1194	1195	(
B-iv-bin-percent	1195	1197	29
I-iv-bin-percent	1197	1198	%
O	1199	1205	versus
B-cv-bin-percent	1206	1208	39
I-cv-bin-percent	1208	1209	%
O	1209	1210	;
O	1211	1212	P
O	1213	1214	=
O	1215	1216	0
O	1216	1217	.
O	1217	1220	005
O	1220	1221	)
O	1221	1222	,
O	1223	1226	and
B-outcome	1227	1236	arthritis
O	1237	1238	(
B-iv-bin-percent	1238	1239	2
I-iv-bin-percent	1239	1240	%
O	1241	1247	versus
B-cv-bin-percent	1248	1249	7
I-cv-bin-percent	1249	1250	%
O	1250	1251	;
O	1252	1253	P
O	1254	1255	=
O	1256	1257	0
O	1257	1258	.
O	1258	1261	006
O	1261	1262	)
O	1263	1271	compared
O	1272	1276	with
O	1277	1287	Caucasians
O	1287	1288	.

O	1289	1293	Mean
O	1294	1300	change
O	1301	1303	in
B-outcome	1304	1307	QOL
I-outcome	1308	1314	scores
O	1315	1318	for
O	1319	1327	minority
O	1328	1333	women
O	1334	1337	who
O	1338	1346	received
O	1347	1356	letrozole
O	1357	1369	demonstrated
O	1370	1378	improved
B-outcome	1379	1385	mental
I-outcome	1386	1392	health
O	1393	1395	at
O	1396	1399	the
O	1400	1401	6
O	1401	1402	-
O	1402	1407	month
O	1408	1418	assessment
O	1419	1420	(
O	1420	1421	P
O	1422	1423	=
O	1424	1425	0
O	1425	1426	.
O	1426	1428	02
O	1428	1429	)
O	1430	1433	and
O	1434	1438	less
B-outcome	1439	1445	bodily
I-outcome	1446	1450	pain
O	1451	1453	at
O	1454	1457	the
O	1458	1460	12
O	1460	1461	-
O	1461	1466	month
O	1467	1477	assessment
O	1478	1479	(
O	1479	1480	P
O	1481	1482	=
O	1483	1484	0
O	1484	1485	.
O	1485	1488	046
O	1488	1489	)
O	1489	1490	.

O	1491	1500	Letrozole
O	1501	1509	improved
B-outcome	1510	1513	DFS
O	1514	1516	in
O	1517	1527	Caucasians
O	1528	1531	but
O	1532	1533	a
O	1534	1542	definite
O	1543	1550	benefit
O	1551	1553	in
O	1554	1562	minority
O	1563	1568	women
O	1569	1572	has
O	1573	1576	not
O	1577	1580	yet
O	1581	1585	been
O	1586	1598	demonstrated
O	1598	1599	.

O	1600	1608	Minority
O	1609	1614	women
O	1615	1624	tolerated
O	1625	1634	letrozole
O	1635	1641	better
O	1642	1646	than
O	1647	1657	Caucasians
O	1658	1660	in
O	1661	1666	terms
O	1667	1669	of
O	1670	1678	toxicity
O	1678	1679	.

O	1680	1685	These
O	1686	1693	results
O	1694	1698	need
O	1699	1711	confirmation
O	1712	1714	in
O	1715	1720	other
O	1721	1727	trials
O	1728	1730	of
O	1731	1740	aromatase
O	1741	1751	inhibitors
O	1751	1752	.
